Abstract:Background: Inflammatory bowel disease (IBD) is a chronic, life-threatening inflammatory disease of gastrointestinal tissue characterized by inflammation of the gut. Recent studies have shown that gut microbiota is involved in the pathophysiology of IBD. However, it is unknown whether direct inhibition of NLR family pyrin domain containing 3 (NLRP3) inflammasome regulates IBD and alters gut microbiota. Methods: Here, the NLRP3 expression was evaluated in the colon of IBD subjects. Then, we investigated the effects of NLRP3 inhibition by MCC950 on the gut microbiota and IBD-like symptoms induced by dextran sulfate sodium (DSS). Results: Firstly, NLRP3 and IL-1B levels were increased in patients with IBD as compared with healthy individuals. Then, the animal experiment showed that NLRP3 inhibition by MCC950 significantly attenuated IBD-like symptoms such as diarrhea and colonic inflammation in DSS-induced mice. In addition, NLRP3 inhibition inhibited NLRP3/ASC/caspase- 1/IL-1B signaling pathway in the colon, which was over-activated by DSS. Furthermore, MCC950 increased the abundance of phylum Firmicutes, decreased the abundance of phylum Bacteroidetes, and increased the Firmicutes/Bacteroidetes ratio, indicating that the inhibition of NLRP3 inflammasome could regulate the abundance of intestinal flora. According to correlation analysis, NLRP3 might produce its functional role in the regulation of oxidation indicators by changing the gut microbiota composition, especially the phylum Bacteroidota, genus Lactobacillus and species Lactobacillus reuteri.Conclusions: This study suggests that NLRP3 inflammasome inhibition attenuates IBD-like symptoms by regulating gut microbiota, and provides a basis for the clinical application of NLRP3 as a target for the treatment of IBD.

Vitamin D Receptor Inhibits NLRP3 Activation by Impeding Its BRCC3-Mediated Deubiquitination.

Vitamin D Receptor Enhances NLRC4 Inflammasome Activation by Promoting NAIPs–NLRC4 Association

Aryl Hydrocarbon Receptor Negatively Regulates NLRP3 Inflammasome Activity by Inhibiting NLRP3 Transcription.

SLC25A3 Negatively Regulates NLRP3 Inflammasome Activation by Restricting the Function of NLRP3

VDR Inhibits NLRP3 Signal in Lupus Nephritis by Competitively Binding with Importin 4 to Suppress NF-κB Nuclear Translocation

Vitamin C inhibits the activation of the NLRP3 inflammasome by scavenging mitochondrial ROS

Negative Regulation Of Nod-Like Receptor Protein 3 Inflammasome Activation By T Cell Ig Mucin-3 Protects Against Peritonitis

Modulatory mechanisms of NLRP3: Potential roles in inflammasome activation

The mechanism of NLRP3 inflammasome activation and its pharmacological inhibitors

NLRP3 Negative Regulation Mechanisms in the Resting State and Its Implications for Therapeutic Development

The E3 Ubiquitin Ligase TRIM65 Negatively Regulates Inflammasome Activation Through Promoting Ubiquitination of NLRP3

Liver X Receptors Agonists Suppress NLRP3 Inflammasome Activation

The E3 Ubiquitin Ligase TRIM31 Attenuates NLRP3 Inflammasome Activation by Promoting Proteasomal Degradation of NLRP3.

CVB3 Inhibits NLRP3 Inflammasome Activation by Suppressing NF-κB Pathway and ROS Production in LPS-Induced Macrophages

Inhibition of NLRP3 Attenuates Sodium Dextran Sulfate-Induced Inflammatory Bowel Disease Through Gut Microbiota Regulation.

ZAP facilitates NLRP3 inflammasome activation via promoting the oligomerization of NLRP3

Pharmacological Inhibitors of the NLRP3 Inflammasome

VCP Inhibition Augments NLRP3 Inflammasome Activation

Negative Regulatory Mechanisms of NLRP3 Inflammasome

1,25(OH)<sub>2</sub>D<sub>3</sub> alleviates DSS-induced ulcerative colitis via inhibiting NLRP3 inflammasome activation

Overexpressed NLRC3 Acts as an Anti-Inflammatory Cytosolic Protein